Literature DB >> 31570596

Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity.

Yuanyan Tan1,2, Athena H Y Chu3, Siyu Bao1,3, Duc Anh Hoang1, Firaol Tamiru Kebede1, Wenjun Xiong1,2, Mingfang Ji4, Jiahai Shi5,2, Zongli Zheng5,2,3.   

Abstract

RNA-guided CRISPR-Cas9 proteins have been widely used for genome editing, but their off-target activities limit broad application. The minimal Cas9 ortholog from Staphylococcus aureus (SaCas9) is commonly used for in vivo genome editing; however, no variant conferring high genome-wide specificity is available. Here, we report rationally engineered SaCas9 variants with highly specific genome-wide activity in human cells without compromising on-target efficiency. One engineered variant, referred to as SaCas9-HF, dramatically improved genome-wide targeting accuracy based on the genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) method and targeted deep sequencing analyses. Among 15 tested human endogenous sites with the canonical NNGRRT protospacer adjacent motif (PAM), SaCas9-HF rendered no detectable off-target activities at 9 sites, minimal off-target activities at 6 sites, and comparable on-target efficiencies to those of wild-type SaCas9. Furthermore, among 4 known promiscuous targeting sites, SaCas9-HF profoundly reduced off-target activities compared with wild type. When delivered by an adeno-associated virus vector, SaCas9-HF also showed reduced off-target effects when targeting VEGFA in a human retinal pigmented epithelium cell line compared with wild type. Then, we further altered a previously described variant named KKH-SaCas9 that has a wider PAM recognition range. Similarly, the resulting KKH-HF remarkably reduced off-target activities and increased on- to off-target editing ratios. Our finding provides an alternative to wild-type SaCas9 for genome editing applications requiring exceptional genome-wide precision.

Entities:  

Keywords:  CRISPR-Cas9; SaCas9; off-target

Year:  2019        PMID: 31570596      PMCID: PMC6800346          DOI: 10.1073/pnas.1906843116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Crystal Structure of Staphylococcus aureus Cas9.

Authors:  Hiroshi Nishimasu; Le Cong; Winston X Yan; F Ann Ran; Bernd Zetsche; Yinqing Li; Arisa Kurabayashi; Ryuichiro Ishitani; Feng Zhang; Osamu Nureki
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

2.  Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition.

Authors:  Benjamin P Kleinstiver; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Ved V Topkar; Zongli Zheng; J Keith Joung
Journal:  Nat Biotechnol       Date:  2015-11-02       Impact factor: 54.908

3.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.

Authors:  Morgan L Maeder; Michael Stefanidakis; Christopher J Wilson; Reshica Baral; Luis Alberto Barrera; George S Bounoutas; David Bumcrot; Hoson Chao; Dawn M Ciulla; Jennifer A DaSilva; Abhishek Dass; Vidya Dhanapal; Tim J Fennell; Ari E Friedland; Georgia Giannoukos; Sebastian W Gloskowski; Alexandra Glucksmann; Gregory M Gotta; Hariharan Jayaram; Scott J Haskett; Bei Hopkins; Joy E Horng; Shivangi Joshi; Eugenio Marco; Rina Mepani; Deepak Reyon; Terence Ta; Diana G Tabbaa; Steven J Samuelsson; Shen Shen; Maxwell N Skor; Pam Stetkiewicz; Tongyao Wang; Clifford Yudkoff; Vic E Myer; Charles F Albright; Haiyan Jiang
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

4.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

5.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

6.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.

Authors:  Shengdar Q Tsai; Nhu T Nguyen; Jose Malagon-Lopez; Ved V Topkar; Martin J Aryee; J Keith Joung
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

7.  A highly specific SpCas9 variant is identified by in vivo screening in yeast.

Authors:  Antonio Casini; Michele Olivieri; Gianluca Petris; Claudia Montagna; Giordano Reginato; Giulia Maule; Francesca Lorenzin; Davide Prandi; Alessandro Romanel; Francesca Demichelis; Alberto Inga; Anna Cereseto
Journal:  Nat Biotechnol       Date:  2018-01-29       Impact factor: 54.908

8.  Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy.

Authors:  Anne Louise Askou; Sidsel Alsing; Josephine N E Benckendorff; Andreas Holmgaard; Jacob Giehm Mikkelsen; Lars Aagaard; Toke Bek; Thomas J Corydon
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-02

9.  Conformational control of DNA target cleavage by CRISPR-Cas9.

Authors:  Samuel H Sternberg; Benjamin LaFrance; Matias Kaplan; Jennifer A Doudna
Journal:  Nature       Date:  2015-10-28       Impact factor: 49.962

10.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  33 in total

1.  CRISPR, animals, and FDA oversight: Building a path to success.

Authors:  Laura R Epstein; Stella S Lee; Mayumi F Miller; Heather A Lombardi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

Review 2.  Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.

Authors:  Mohammad Mijanur Rahman; Trygve O Tollefsbol
Journal:  Methods       Date:  2020-04-18       Impact factor: 3.608

Review 3.  Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing.

Authors:  Roy Rabinowitz; Daniel Offen
Journal:  Mol Ther       Date:  2020-11-26       Impact factor: 11.454

Review 4.  Regulating CRISPR/Cas9 Function through Conditional Guide RNA Control.

Authors:  Wes Brown; Wenyuan Zhou; Alexander Deiters
Journal:  Chembiochem       Date:  2020-11-17       Impact factor: 3.164

Review 5.  A Guide to Understanding "State-of-the-Art" Basic Research Techniques in Anesthesiology.

Authors:  Detlef Obal; Shaogen Wu; Andrew McKinstry-Wu; Vivianne L Tawfik
Journal:  Anesth Analg       Date:  2020-08       Impact factor: 6.627

Review 6.  The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.

Authors:  Jingyi Wang; Chenzi Zhang; Bo Feng
Journal:  J Cell Mol Med       Date:  2020-02-10       Impact factor: 5.310

7.  An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue.

Authors:  Jiankang Jin; Yan Xu; Longfei Huo; Lang Ma; Ailing W Scott; Melissa Pool Pizzi; Yuan Li; Ying Wang; Xiaodan Yao; Shumei Song; Jaffer A Ajani
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

8.  Efficient TALEN-mediated gene knockin at the bovine Y chromosome and generation of a sex-reversal bovine.

Authors:  Ming Wang; ZhaoLin Sun; Fangrong Ding; Haiping Wang; Ling Li; Xue Li; Xianjin Zheng; Ning Li; Yunping Dai; Changxin Wu
Journal:  Cell Mol Life Sci       Date:  2021-05-28       Impact factor: 9.261

Review 9.  Recent Advances and Future Perspectives of In Vivo Targeted Delivery of Genome-Editing Reagents to Germ Cells, Embryos, and Fetuses in Mice.

Authors:  Masahiro Sato; Shuji Takabayashi; Eri Akasaka; Shingo Nakamura
Journal:  Cells       Date:  2020-03-26       Impact factor: 6.600

10.  Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9.

Authors:  Zhiquan Liu; Siyu Chen; Wanhua Xie; Yuning Song; Jinze Li; Liangxue Lai; Zhanjun Li
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.